DECIPHER - Site Hamburg, Germany
The Institute of Clinical Pharmacology and Toxicology (Director: Prof. Dr. Rainer H. Böger) at the University Medical Center Hamburg-Eppendorf (Germany) is the coordinating partner of DECIPHER.
The institute has a long-standing expertise in research of new biomarkers for cardiometabolic diseases.
Under the leadership of Dr. Juliane Hannemann as the responsible scientist, the major focus is on studying the molecular mechanisms of hypoxic changes induced in the lung and in other tissues and organs.
Contact Site Hamburg:
Institute of Clinical Pharmacology and Toxicology
Martinistr. 52, N30
20246 Hamburg, Germany
|Prof. Dr. Rainer Böger|
Phone: +49 (0)40 7410-59759
|Dr. Juliane Hannemann|
Phone: +49 (0)40 7410-59701
DECIPHER - Site Iquique, Chile
The Institute of Health Studies – Medicine of High Altitude at the University Arturo Prat in Iquique (Chile) is the Chilean founding partner of DECIPHER.
Under the leadership of Prof. Dr. Julio Brito and Prof. Dr. Patricia Siques, the institute is specialized on research into the physiological mechanisms of adaptation to high altitude and the pathophysiological causes of altitude-associated diseases; its main focus is on the metabolic and cardiovascular changes on the molecular and epidemiological levels.
Contact Site Iquique:
Institute of Health Studies
Universidad Arturo Prat
Avda. Arturo Prat 2120
|Prof. Dr. Julio Brito|
|Prof. Dr. Patricia Siques|
DECIPHER - Partners
Fraunhofer Institute for Toxicology and Experimental Medicine (FhG-ITEM), Hannover, Germany
Partner for the project DECIPHER is the Division of Airway Research (Head: Prof. Dr. Jens Hohlfeld, MD), Fraunhofer Institute for Toxicology and Experimental Medicine in Hannover. With its Departments of Clinical Airway Research and of Biomarker Analytics and Development, several clinical challenge models (e.g. normobaric hypoxia challenge) have been successfully implemented during recent years and non-invasive methods for monitoring of airway inflammation and systemic metabolism have been established. Current work focuses on the characterization of cellular mechanisms in airway diseases by chipcytometry using artificial intelligence for analysis of big data.